[Congenital Chagas disease: experience in the Hospital de Niños, Ricardo Gutiérrez, Buenos Aires, Argentina].

Servicio de Parasitología y Enfermedad de Chagas, Hospital de Niños R Gutiérrez, Gallo 1330 (1425), Buenos Aires, Argentina.
Revista da Sociedade Brasileira de Medicina Tropical (Impact Factor: 0.94). 01/2005; 38 Suppl 2:41-5.
Source: PubMed

ABSTRACT Epidemiological, clinical, diagnostic, and therapeutic data from children who were born to mothers infected with T. cruzi who came to our hospital are presented. In addition, we exhibit the preliminary results of a technique that detects the anti F2/3 antibodies: these would be able to confirm the cure earlier than conventional serology. We also show the results of PCR diagnosis. Most of the mothers (76,1%) resided in Argentina, the rest were from Bolivia and Paraguay The median average age at diagnosis of the patients was 8,5 months (range 15 days-10 years). Out of 168 children, 64,98% were asymptomatic at diagnosis. The diagnosis criteria were: T. cruzi observation by microhematocrit technique in patients less than 7 month old. Two reactive serological tests in patients older than 8 months. A nifurtimox dose used in these patients was 10-13 mg/kg/d during 60 days. Although 31% presented side effects, none of them had to be dropped from the treatment. Cure criteria was conventional serology negativization. Of the patient population, we cured 87,2% of them, 98% of those under 3 years, and 100% of those who received treatment before age 8 months. We compared the time of negativization between conventional serology and anti F2/3 in 21 children. The latter were very useful to demonstrate (p>0,001) the success of the treatment, in those that started treatment after 8 months of age. PCR testing of a group of all patients, showed a diagnostic sensibility of 80,3% and a specificity of 97,8%.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Monitoring the drug benznidazole in biological fluids is a powerful tool for clinical diagnostic and pharmacological studies in chagasic patients. However, research in this concern needs to be done. The accurate quantitation of this drug in complex matrices represents a highly challenging task complicated by the absence of sensitive analytical methods. It follows that sample processing strategies, preparation/cleanup procedures, and chromatographic/ionization/detection parameters, were evaluated for method optimization. The summation of this work generated a rapid, selective, sensitive methodology based on reversed-phase chromatography-tandem mass spectrometry for the analysis of benznidazole in urine samples. To the best of our knowledge, this is a first report of a LC-MS/MS platform employed for this application. Matrix effect was determined; a 90% of signal suppression was observed. The limits of detection and quantification were 0.75 and 4.85μgL(-1); respectively. The latter allowed the method׳s application to the detection of benznidazole in clinical studies and pharmacological monitoring analysis.
    Talanta 01/2015; 131C:656-660. DOI:10.1016/j.talanta.2014.08.040 · 3.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chagas disease is a parasitic disease endemic to the Americas. Long term complications include severe cardiac involvement, which can lead to severe disability and death of affected individuals. Treatment options for Chagas disease are limited to 2 drugs (benznidazole and nifurtimox), but knowledge of the pharmacology of these drugs is lacking, particularly in childhood. To date, no pharmacokinetics data are available in children. We conducted the first population pharmacokinetic study of benznidazole in children. Interestingly, we found that elimination of the drug is significantly faster in children than in adults, leading to lower plasma concentrations. However, unlike adults, all children in the study responded well and had few adverse reactions to the drug. These findings suggest that adjustment of current adult doses may be beneficial.
    PLoS Neglected Tropical Diseases 05/2014; 8(5):e2907. DOI:10.1371/journal.pntd.0002907 · 4.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Few studies have assessed the burden of Chagas disease in non-endemic countries and most of them are based on prevalence estimates from Latin American (LA) countries that likely differ from the prevalence in migrants living in Europe. The aim of this study was to systematically review the existing data informing current understanding of the prevalence of Chagas disease in LA migrants living in European countries. We conducted a systematic review and meta-analysis of studies reporting prevalence of Chagas disease in European countries belonging to the European Union (EU) before 2004 in accordance with the MOOSE guidelines and based on the database sources MEDLINE and Global Health. No restrictions were placed on study date, study design or language of publication. The pooled prevalence was estimated using random effect models based on DerSimonian & Laird method. We identified 18 studies conducted in five European countries. The random effect pooled prevalence was 4.2% (95%CI:2.2-6.7%); and the heterogeneity of Chagas disease prevalence among studies was high (I2 = 97%,p<0.001). Migrants from Bolivia had the highest prevalence of Chagas disease (18.1%, 95%CI:13.9-22.7%). Prevalence of Chagas in LA migrants living in Europe is high, particularly in migrants from Bolivia and Paraguay. Data are highly heterogeneous dependent upon country of origin and within studies of migrants from the same country of origin. Country-specific prevalence differs from the estimates available from LA countries. Our meta-analysis provides prevalence estimates of Chagas disease that should be used to estimate the burden of disease in European countries.
    PLoS neglected tropical diseases 02/2015; 9(2):e0003540. DOI:10.1371/journal.pntd.0003540 · 4.72 Impact Factor